APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
Management of OFEV®-related diarrhoea
Document ID: PC-MY-101490
07/01/2022
Author: Boehringer Ingelheim
A guide to management of OFEV® related diarrhoea
References:
1. Raghu G, et al. Am J Respir Crit Care Med. 2011;183(6):788-824.
2. Song JW, et al. Eur Respir J. 2011;37(2):356-363.
3. Richeldi L, et al. N Engl J Med. 2014;370(22):2071-2082.
4. Richeldi L, et al. Respir Med. 2016;113:74-79.
RELATED CONTENT
PC-MY-101490
Production date: January 2022
Production date: January 2022